OmniAb Investor Presentation Deck

Approved, Under Regulatory Review and Clinical-Stage Partner Pipeline AS OF 06/30/2023 Partner gloria #ARCUS GILEAD Zimberelimab C Sugemalimab Teclistamab Batoclimab Tiragolumab GEN1046 M6223 APVO436 JNJ-70218902 JNJ-78306358 1351 Ins 基石药业 CSTONE Janssen th HANALL>< HARBOUR IMMUNOVANT Genentech A Member of Genmab BIONTECH Janssen Ichen MERCK Aptevo Janssen effles Genmab OCTTQ Capu symphogen a Servier Company Pfizer symphogen a Servier Company symphogen Servier Company abbvie AstraZeneca AMGEN SalubrisBio Zhilkang Hongyi Genmab CURON Boehringer Ingelheim Undisclosed Merck Janssen chan-plan BIONTECH Seagen HANALL><IMMUNOVANT gloria譽衡生物 Program GEN1047 S095017 S095018 S095024 S095029 ABBV-383 TNB-486 AMG 340 SAL003 Undisclosed CN1 Undisclosed Undisclosed M9140 GEN1053 JNJ-79635322 SGEN-BB228 IMVT-1402 GLS-012 Source Animal OmniRat OmniRat OmniRat OmniRat OmniRat OmniRat OmniRat OmniMouse OmniRat OmniRat OmniRat OmniRat OmniRat OmniRat OmniRat OmniFlic OmniFlic OmniFlic OmniRat OmniRat OmniRat OmniChicken OmniRat OmniRat OmniRat OmniRat OmniRat OmniRat OmniRat Therapy Area Oncology Oncology Oncology Immunology Oncology Oncology Oncology Oncology Oncology Oncology Oncology Oncology Oncology Oncology Oncology Oncology Oncology Oncology Metabolic Oncology Oncology Undisclosed Gastrointestinal Oncology Oncology Oncology Oncology Immunology Oncology Target PD-1 PD-L1 BCMA x CD3 FcRn TIGIT PD-L1 x 4-1BB TIGIT CD123 x CD3 Undisclosed HLA-G x CD3 B7H4 x CD3 LAG-3 TIM-3 CD73 NKG2A BCMA x CD3 CD19 x CD3 PSMA x CD3 PCSK9 Undisclosed Undisclosed Undisclosed Undisclosed CEACAM-5 CD27 Undisclosed CD228 x 4-1BB FcRn LAG-3 Phase 1 Phase 2 Phase 3 Registration Animal launch year: OmniRat 2012; OmniMouse 2014; OmniFlic 2014; OmniChicken 2016; OmniClic 2019; OmniTaur 2020 Notes: Most advanced status for each program shown. Zimberelimab and Sugemalimab are approved and marketed in China. Teclistamab is approved and marketed in the US and EU with $35M launch milestones paid. Indicates program with fully paid license from OMT, Inc. prior to acquisition. Programs discovered by Teneobio under a fully paid license. Future programs discovered under license agreement are subject to downstream economics. Approved 35 OmniAb

View entire presentation